Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan 31;22(1):86-93.
doi: 10.5056/jnm15124.

Recurrence and Its Impact on the Health-related Quality of Life in Patients with Gastroesophageal Reflux Disease: A Prospective Follow-up Analysis

Yang Won Min  1 , Yong Woon Shin  2 , Gab Jin Cheon  3 , Kyung Sik Park  4 , Hyun Soo Kim  5 , Chong-Il Sohn  6 , Tae Nyeun Kim  7 , Hyeung Cheol Moon  8 , Poong-Lyul Rhee  1
Affiliations

Recurrence and Its Impact on the Health-related Quality of Life in Patients with Gastroesophageal Reflux Disease: A Prospective Follow-up Analysis

Yang Won Min et al. J Neurogastroenterol Motil. .

Abstract

Background/aims: Limited data exist on the outcome of gastroesophageal reflux disease (GERD) treatment and its impact on the health-related quality of life (HRQoL) in the Asian population. This study aims to evaluate the treatment outcomes, to investigate the factors associated with recurrence, and to evaluate the impact of the treatment outcome on the HRQoL in a Korean GERD population.

Methods: This was a prospective, multicenter study involving a total of 824 GERD patients. The response to treatment was assessed at week 4 (or week 8 for the patients who did not achieve complete resolution [CR] at week 4). The EQ-5D questionnaire was used at baseline, end of treatment, and first recurrence to assess the HRQoL. To assess GERD symptoms, contact of patients by phone at 1, 6, and 12 months following treatment was carried out.

Results: CR was achieved in 65.6% and recurrence was observed in 47.8% following treatment. CR and recurrence rates did not differ by the presence of esophagitis. Multivariate analysis revealed that acid regurgitation (odds ratio 2.249; 95% confidence interval 1.293-3.912; P= 0.004) and both acid regurgitation and heartburn (odds ratio 2.330; 95% confidence interval 1.392-3.901; P= 0.001) were independent risk factors for GERD recurrence. EQ-5D scores were more improved in patients with CR than in those without CR, and worsened more during follow-up in patients with recurrence than in those without recurrence.

Conclusions: We should achieve complete symptom relief and attempt to prevent recurrence in GERD patients to improve their HRQoL.

Keywords: Gastroesophageal reflux; Quality of life; Recurrence; Therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patients flow.
Figure 2
Figure 2
Response at the end of the treatment. Among the 611 subjects assessed, a complete resolution was present in 401 (65.6%), a satisfactory resolution in 132 (21.6%), a partial response in 70 (11.5%) and a refractory response in 8 (1.3%). The treatment response did not differ between patients with erosive reflux disease (ERD) and non-erosive reflux disease (NERD).
Figure 3
Figure 3
Change in health-related quality of life after the end of treatment according to the presence of recurrence. The EQ descriptive score and the visual analogue scale (VAS) score shows a greater improvement in subjects with complete resolution compared with those without complete resolution.
Figure 4
Figure 4
Change of health-related quality of life after the end of treatment according to the presence of recurrence. EQ descriptive score worsened during follow-up in subjects with recurrence compared with those without recurrence, while EQ visual analogue scale (VAS) score did not differ between subjects with and without recurrence.
See this image and copyright information in PMC

References

    1. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308–328. doi: 10.1038/ajg.2012.444. - DOI - PubMed
    1. Bader JP, Delchier JC. Clinical efficacy of pantoprazole compared with ranitidine. Aliment Pharmacol Ther. 1994;8(suppl 1):47–52. doi: 10.1111/j.1365-2036.1994.tb00247.x. - DOI - PubMed
    1. Schindlbeck NE, Klauser AG, Berghammer G, Londong W, Müller-Lissner SA. Three year follow up of patients with gastrooesophageal reflux disease. Gut. 1992;33:1016–1019. doi: 10.1136/gut.33.8.1016. - DOI - PMC - PubMed
    1. Wong BC, Kinoshita Y. Systematic review on epidemiology of gastroesophageal reflux disease in Asia. Clin Gastroenterol Hepatol. 2006;4:398–407. doi: 10.1016/j.cgh.2005.10.011. - DOI - PubMed
    1. Bai Y, Du Y, Zou D, et al. Gastroesophageal reflux disease questionnaire (GerdQ) in real-world practice: a national multicenter survey on 8065 patients. J Gastroenterol Hepatol. 2013;28:626–631. doi: 10.1111/jgh.12125. - DOI - PubMed

LinkOut - more resources